Demand for weight-loss medications balances price pressure, and Lilly increases its profit prediction

Strong demand for Lilly’s GLP-1 weight-loss and diabetes medications helped offset declining prices in U.S. and foreign markets. Causing the company to considerably increase its full-year earnings and sales guidance on Thursday, increasing its shares by more than 6%.

As pricing pressures increase, investors continue to focus on whether the U.S. pharmaceutical company can maintain its trend. Due to negotiated discounts and agreements with the Trump administration. Lilly has been operating at lower realized prices, which raises concerns about how well company will continue to convert robust demand into revenue growth.

Indianapolis-based pharmaceutical business announced adjusted earnings of $8.55 per share, significantly higher than Wall Street projections of $6.66, according to LSEG data, which should allay some investor fears.

Lower end of Lilly’s new 2026 earnings guidance range is now higher than its previous upper limit. Now the company now projects adjusted earnings of $35.50 to $37.00 per share, up from $33.50 to $35.00. Analysts had estimated $34.55 per share. Lilly expects revenue of $82 billion to $85 billion, compared to its previous forecast of $80 billion to $83 billion.

Prediction to reach 150 billion on the next decade

Lilly is competing with Danish pharmaceutical company Novo Nordisk in the growing market for new weight-loss drugs. Which analysts predict will reach $150 billion annually over the next decade. In November, both companies reached agreements with President Donald Trump’s administration to lower the prices of their obesity medications in the United States.

According to Lilly, Foundayo was being offered by over 12 large telemedicine providers, accounting for roughly 35% of the launch volume, and the US launch had gotten off to a great start.

The CEO David Ricks anticipates that Foundayo will increase the number of individuals who can take use of GLP-1s.

Investors will be seeking additional clarification on Foundayo’s launch dynamics and the larger obesity franchise. Which are critical to sustaining momentum, even though «it’s really hard to ask for a better quarter.»

Also read: Carlos Hank Gonzalez: “The greatest competitive advantage is being with Mexico and for Mexico”